Pilot Sub-Study of the Effect of Hepatitis C Cure by Glecaprevir/Pibrentasvir on the Gut Microbiome of Patients with Chronic Hepatitis C Genotypes 1 to 6 in the Mythen Study

• Egile Nagusiak: Bahtiyar Yilmaz (Egilea), Lisa Ruckstuhl (Egilea), Beat Müllhaupt (Egilea), Lorenzo Magenta (Egilea), Melanie Harrer Kuster (Egilea), Olivier Clerc (Egilea), Ralph Torgler (Egilea), Nasser Semmo (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2021-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

In this small pilot sub-study, longitudinal gut microbiota composition changes, after successful treatment of hepatitis C virus (HCV) with the co-formulated glecaprevir/pibrentasvir (GLE/PIB), were analyzed before treatment (baseline) and 12 weeks post-treatment. Participating patients provided a fr...